CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-24342
Recombinant Monoclonal Antibody
![CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free [NBP3-24342] -](https://resources.bio-techne.com/images/products/nbp3-24342_rabbit-cd27-tnfrsf7-mab-lpfs2-8838r-azide-and-bsa-free-24120257592817.jpg "Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free [NBP3-24342] -")
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry-Paraffin
Label
Unconjugated
Antibody Source
Monoclonal Rabbit IgG Kappa Clone # LPFS2/8838R
Format
Azide and BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
Recombinant human full-length CD27/TNFRSF7 protein (exact sequence is proprietary)
Localization
Cell Surface.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Kappa
Description
Antibody without azide - store at -20 to -80C.
Scientific Data Images for CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free
Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free [NBP3-24342] -
Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free [NBP3-24342] - Formalin-fixed, paraffin-embedded human lymph node stained with CD27/TNFRSF7 Antibody (LPFS2/8838R). Inset: PBS instead of primary antibody; secondary only negative control.![CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free [NBP3-24342] -](https://resources.bio-techne.com/images/products/nbp3-24342_rabbit-cd27-tnfrsf7-mab-lpfs2-8838r-azide-and-bsa-free-2412025801668.jpg "Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free [NBP3-24342] -")
Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free [NBP3-24342] -
Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free [NBP3-24342] - Formalin-fixed, paraffin-embedded human lymph node stained with CD27/TNFRSF7 Antibody (LPFS2/8838R). HIER: Tris/EDTA, pH9.0, 45min. 2°C: HRP-polymer, 30min. DAB, 5min.Applications for CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free
Application
Recommended Usage
Immunohistochemistry-Paraffin
1-2ug/ml
Application Notes
Immunohistochemistry-Paraffin: 1-2ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes. Optimal dilution for a specific application should be determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
10mM PBS
Format
Azide and BSA Free
Preservative
No Preservative
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20 to -80C. Avoid freeze-thaw cycles.
Background: CD27/TNFRSF7
Membrane-bound CD27 is expressed as a disulfide-linked homodimer (3). CD27 binds to the ligand CD70, a transmembrane glycoprotein that is transiently expressed on activated immune cells such as antigen presenting cells (APCs), dendritic cells (DCs), NK cells, B cells, and T cells (1,2,6,7). The receptor-ligand binding interaction leads to NFkappaB and c-Jun pathway activation which promotes immune stimulation and activation and survival of CD4+ T cells, CD8+ T cells, memory T cells, and NK cells (2,6,7). Both CD27 and CD70 are often abnormally expressed or dysregulated on malignant and cancer cells leading to immune evasion and tumor progression (7). CD27 has become a target of interest of immunotherapies for viral infections, autoimmune disease, and cancer (2). Varlilumab, an agonistic CD27 monoclonal antibody (mAB), has entered clinical trials for the treatment of hematological and solid tumor cancers (1,6). Additional clinical trials are in process that combine varlilumab with other immune checkpoint inhibitors like the programmed cell death protein-1 (PD-1) blocking mAb nivolumab (1,2). Initial results are promising, suggesting that targeting CD27, especially in combination with other therapeutics, may be a promising and effective immunotherapy for a variety of pathologies (1,2,6).
References
1. Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020;4(Suppl 3):e000629. https://doi.org/10.1136/esmoopen-2019-000629
2. Grant EJ, Nussing S, Sant S, Clemens EB, Kedzierska K. The role of CD27 in anti-viral T-cell immunity. Curr Opin Virol. 2017;22:77-88. https://doi.org/10.1016/j.coviro.2016.12.001
3. Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39-48. https://10.1182/blood-2017-07-741025
4. Uniprot (P26842)
5. Uniprot (P41272)
6. van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7(6):655-667. https://doi.org/10.2217/imt.15.32
7. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41(1):12. https://doi.org/10.1186/s13046-021-02215-y
Alternate Names
CD27, TNFRSF7
Gene Symbol
CD27
Additional CD27/TNFRSF7 Products
Product Documents for CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free
Product Specific Notices for CD27/TNFRSF7 Antibody (LPFS2/8838R) - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...